Cheng Ying (oncologist)

  1. Home
  2. Wiki
Cheng Ying
Born1963
DiedJuly 2025 (2025-08) (aged 61)
Medical career
InstitutionsJilin Cancer Hospital

Cheng Ying (Chinese: 程颖; 1963 – July 2025) was a Chinese oncologist, physician-scientist, and hospital administrator. She was the director of Jilin Cancer Hospital and a leading figure in cancer research in China, particularly in the field of lung cancer.[1] Her work as a principal investigator for major clinical trials, including studies funded by AstraZeneca, earned her international recognition.[2]

Early life and education

[edit]

Cheng Ying was born in 1963. She graduated from Bethune Medical University (now part of Jilin University) in July 1986, embarking on a career in medicine that would span nearly four decades.[3]

Career

[edit]

Cheng spent her entire career at Jilin Cancer Hospital, where she held numerous positions of increasing responsibility, including director, deputy president, president, and party secretary. She was also the director of the Jilin Provincial Cancer Center and the Jilin Provincial Lung Cancer Diagnosis and Treatment Center.[3]

Cheng held several key leadership roles in professional organizations. She served as the vice president of the Chinese Society of Clinical Oncology (CSCO) and was the chairwoman of the CSCO Small Cell Lung Cancer Committee. Additionally, she was the vice-chairman of the Lung Cancer Professional Committee of the Chinese Anti-Cancer Association.[3]

In 2009, she received the Chinese Physician Award, the highest honor for a medical professional in China. In 2014, the Chinese Hospital Association named her an "Outstanding Hospital President."[3]

Research and clinical trials

[edit]

Cheng played a foundational role in advancing China's clinical trials for tumor diseases, developing a particular expertise in small-cell lung cancer (SCLC). Her standing as the nation's leading principal investigator was substantiated by data; she held the top national rank for seven consecutive years (from 2018) based on the volume of newly initiated clinical trials. A 2019 report evaluating investigators of tumor trials further confirmed her preeminence, ranking her first in multiple statistical categories.[4][5]

One of her most significant contributions was her role as the lead principal investigator for the ADRIATIC study, a global clinical trial funded by AstraZeneca. The results of this study, published in The New England Journal of Medicine in September 2024, demonstrated that the immunotherapy drug durvalumab significantly improved overall and progression-free survival for patients with limited-stage small-cell lung cancer after chemoradiotherapy. This was considered a landmark achievement in the treatment of this aggressive form of cancer.[6]

Death

[edit]

Cheng died suddenly in early July 2025 at the age of 62. The cause of death was not publicly announced. Her last public appearance was reportedly on May 10, 2025, at the annual meeting of the small-cell carcinoma committee of the Chinese Anti-Cancer Association.[3]

References

[edit]
  1. ^ 复宏汉霖与吉林省肿瘤医院签订战略合作协议，共同推进抗肿瘤生物药研发创新-新闻中心 [Henlius Signs Strategic Cooperation Agreement with Jilin Cancer Hospital to Jointly Advance Innovation in Anticancer Biologics R&D]. Henlius.
  2. ^ 程颖代表的一份建议：建立吉林省县域医疗机构肿瘤防控体系 [Cheng Ying's Proposal: Establishing a Cancer Prevention and Control System in County-Level Medical Institutions in Jilin Province]. Jilin Provincial People's Congress Standing Committee.
  3. ^ a b c d e "Top Chinese oncologist and director of Jilin Cancer Hospital, Cheng Ying, dies". South China Morning Post. 9 July 2025.
  4. ^ Cui, Lisa (31 October 2024). "Dr. Ying Cheng: New Approaches in Radiotherapy and Immunotherapy, Leading a New Era in the Treatment of Unresectable Lung Cancer". MediaMedic.
  5. ^ "ASTRUM-005: The first immunotherapy clinical study of SCLC published in JAMA, one of the top medical journals in the world-Media". Henlius.
  6. ^ 专家说丨程颖教授：ASTRUM-005研究4年OS率高达21.9%，点亮ES-SCLC患者临床治愈新希望医药新闻-ByDrug-一站式医药资源共享中心-医药魔方 [Professor Cheng Ying: ASTRUM-005 Study Achieves 4-Year Overall Survival Rate of 21.9%, Sparking New Hope for Clinical Cure in ES-SCLC Patients]. bydrug.pharmcube.com.